$884 Million is the total value of Omega Fund Management, LLC's 23 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 4.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NUVB | Nuvation Bio | $262,657,000 | -10.9% | 28,212,376 | 0.0% | 29.73% | +6.6% | |
| REPL | Replimune Group | $192,417,000 | +25.9% | 5,008,245 | 0.0% | 21.78% | +50.7% | |
| MORF | Sell | Morphic Holding | $101,428,000 | -29.5% | 1,767,350 | -22.2% | 11.48% | -15.6% |
| KRON | Kronos Bio | $91,448,000 | -18.2% | 3,818,283 | 0.0% | 10.35% | -2.1% | |
| IKNA | Ikena Oncology | $31,578,000 | -50.3% | 2,249,123 | 0.0% | 3.57% | -40.5% | |
| GOSS | Gossamer Bio | $26,963,000 | -12.2% | 3,320,608 | 0.0% | 3.05% | +5.1% | |
| SPRB | Spruce Biosciences | $24,225,000 | -32.5% | 2,161,022 | 0.0% | 2.74% | -19.2% | |
| IMUX | Immunic | $21,923,000 | -23.1% | 1,788,160 | 0.0% | 2.48% | -8.0% | |
| PRTK | Paratek Pharmaceuticals | $17,735,000 | -3.4% | 2,600,410 | 0.0% | 2.01% | +15.5% | |
| ARQT | Arcutis Biothereapeutics | $17,024,000 | -5.7% | 623,836 | 0.0% | 1.93% | +12.9% | |
| SANA | Sana Biotechnology, Inc. | $16,588,000 | -41.3% | 843,750 | 0.0% | 1.88% | -29.7% | |
| AVIR | Sell | Atea Pharmaceuticals | $16,043,000 | -69.3% | 746,868 | -11.8% | 1.82% | -63.3% |
| SYRS | Buy | Syros Pharmaceuticals | $12,398,000 | +6.1% | 2,274,831 | +45.6% | 1.40% | +26.9% |
| ALPN | Alpine Immune Sciences | $11,564,000 | -15.1% | 1,284,900 | 0.0% | 1.31% | +1.6% | |
| EPIX | Sell | ESSA Pharma | $9,377,000 | -4.2% | 328,196 | -2.6% | 1.06% | +14.6% |
| CMPI | Checkmate Pharmaceuticals | $7,957,000 | -50.9% | 1,335,050 | 0.0% | 0.90% | -41.2% | |
| OMEG | Omega Alpha SPAC | $4,985,000 | -0.3% | 501,000 | 0.0% | 0.56% | +19.2% | |
| CDTX | Cidara Therapeutics | $4,051,000 | -24.1% | 2,005,249 | 0.0% | 0.46% | -9.3% | |
| FGEN | FibroGen | $3,479,000 | -23.3% | 130,646 | 0.0% | 0.39% | -8.2% | |
| OBSV | ObsEva | $3,028,000 | -6.8% | 999,364 | 0.0% | 0.34% | +11.7% | |
| TRVI | Trevi Therapeutics | $2,843,000 | -17.0% | 1,263,408 | 0.0% | 0.32% | -0.6% | |
| IMCR | Immunocore Holdings | $2,012,000 | -8.3% | 51,535 | 0.0% | 0.23% | +9.6% | |
| JNCE | Jounce Therapeutics | $1,873,000 | -33.8% | 275,513 | 0.0% | 0.21% | -20.9% | |
| PIRS | Exit | Pieris Pharmaceuticals | $0 | – | -225,741 | -100.0% | -0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.